Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

FGF23 induces left ventricular hypertrophy.

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M.

J Clin Invest. 2011 Nov;121(11):4393-408. doi: 10.1172/JCI46122.

2.

Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.

Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstädt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C.

Cell Metab. 2015 Dec 1;22(6):1020-32. doi: 10.1016/j.cmet.2015.09.002.

3.

Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.

Leifheit-Nestler M, Große Siemer R, Flasbart K, Richter B, Kirchhoff F, Ziegler WH, Klintschar M, Becker JU, Erbersdobler A, Aufricht C, Seeman T, Fischer DC, Faul C, Haffner D.

Nephrol Dial Transplant. 2016 Jul;31(7):1088-99. doi: 10.1093/ndt/gfv421.

PMID:
26681731
4.

Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.

Hsu HJ, Wu MS.

Am J Med Sci. 2009 Feb;337(2):116-22. doi: 10.1097/MAJ.0b013e3181815498.

PMID:
19214027
5.

Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.

Di Marco GS, Reuter S, Kentrup D, Grabner A, Amaral AP, Fobker M, Stypmann J, Pavenstädt H, Wolf M, Faul C, Brand M.

Nephrol Dial Transplant. 2014 Nov;29(11):2028-35. doi: 10.1093/ndt/gfu190.

6.

Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.

Jovanovich A, Ix JH, Gottdiener J, McFann K, Katz R, Kestenbaum B, de Boer IH, Sarnak M, Shlipak MG, Mukamal KJ, Siscovick D, Chonchol M.

Atherosclerosis. 2013 Nov;231(1):114-9. doi: 10.1016/j.atherosclerosis.2013.09.002.

7.

FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.

Touchberry CD, Green TM, Tchikrizov V, Mannix JE, Mao TF, Carney BW, Girgis M, Vincent RJ, Wetmore LA, Dawn B, Bonewald LF, Stubbs JR, Wacker MJ.

Am J Physiol Endocrinol Metab. 2013 Apr 15;304(8):E863-73. doi: 10.1152/ajpendo.00596.2012.

8.

Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy.

Yang K, Wang C, Nie L, Zhao X, Gu J, Guan X, Wang S, Xiao T, Xu X, He T, Xia X, Wang J, Zhao J.

J Am Soc Nephrol. 2015 Oct;26(10):2434-46. doi: 10.1681/ASN.2014060543.

9.

The role of fibroblast growth factor-23 in cardiorenal syndrome.

Kovesdy CP, Quarles LD.

Nephron Clin Pract. 2013;123(3-4):194-201. doi: 10.1159/000353593. Review.

10.

Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.

Xie J, Yoon J, An SW, Kuro-o M, Huang CL.

J Am Soc Nephrol. 2015 May;26(5):1150-60. doi: 10.1681/ASN.2014040325.

11.

Fibroblast growth factor-23 and cardiac structure and function.

Agarwal I, Ide N, Ix JH, Kestenbaum B, Lanske B, Schiller NB, Whooley MA, Mukamal KJ.

J Am Heart Assoc. 2014 Feb 13;3(1):e000584. doi: 10.1161/JAHA.113.000584.

12.

Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.

Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE.

Atherosclerosis. 2009 Dec;207(2):546-51. doi: 10.1016/j.atherosclerosis.2009.05.013.

PMID:
19524924
13.

[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23-Klotho axis in CKD-MBD].

Komaba H.

Clin Calcium. 2010 Jul;20(7):1028-36. doi: CliCa100710281036. Review. Japanese.

PMID:
20585181
14.

Fibroblast growth factor 23 and the heart.

Faul C.

Curr Opin Nephrol Hypertens. 2012 Jul;21(4):369-75. doi: 10.1097/MNH.0b013e32835422c4. Review.

PMID:
22531163
15.

Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients.

Unver S, Kavlak E, Gümüsel HK, Celikbilek F, Esertas K, Muftuoglu T, Kirilmaz A.

Ren Fail. 2015 Jul;37(6):951-6. doi: 10.3109/0886022X.2015.1052945.

PMID:
26030798
16.

Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.

Seifert ME, de Las Fuentes L, Ginsberg C, Rothstein M, Dietzen DJ, Cheng SC, Ross W, Windus D, Dávila-Román VG, Hruska KA.

Am J Nephrol. 2014;39(5):392-9. doi: 10.1159/000362251.

17.

S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner.

Yan L, Mathew L, Chellan B, Gardner B, Earley J, Puri TS, Hofmann Bowman MA.

Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1399-411. doi: 10.1161/ATVBAHA.114.303508.

18.

Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients.

Krajisnik T, Olauson H, Mirza MA, Hellman P, Akerström G, Westin G, Larsson TE, Björklund P.

Kidney Int. 2010 Nov;78(10):1024-32. doi: 10.1038/ki.2010.260.

20.

Regulation of fibroblast growth factor-23 signaling by klotho.

Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M.

J Biol Chem. 2006 Mar 10;281(10):6120-3.

Items per page

Supplemental Content

Support Center